New combo therapy aims to keep advanced lung cancer in check
NCT ID NCT03559049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a combination of two drugs, rucaparib and pembrolizumab, could help people with stage IV non-small cell lung cancer keep their cancer from growing after initial treatment. The study included 25 adults whose cancer had not gotten worse after standard chemotherapy and immunotherapy. The goal was to see how long the cancer stayed under control and how safe the combination was.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use
- Could a cancer drug fight the wasting away seen in advanced lung cancer?
- Targeted drug shows promise for Gene-Driven lung cancers
- Gene-Hacked immune cells take on tough cancers
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New radiation approach targets multiple tumors at once in early trial